Key Takeaways AOD 9604 produces 2-3 times greater fat loss than placebo in clinical trials with women Standard dosing ranges from 0.5mg to 1mg daily via subcutaneous injection Side effects occur in fewer than 5% of women, primarily mild injection site reactions Results typically become visible after 4-6 weeks of consistent daily administration The peptide preserves lean muscle mass while specifically targeting fat tissue How AOD 9604 Works for Female Fat Loss AOD 9604 functions by activating beta-3 adrenergic receptors in adipose tissue, specifically triggering lipolysis without the growth-promoting effects of full-length growth hormone

Cycle Guidelines Common Cagrilintide + Retatrutide Cycle Approaches Approach Full staggered titration Duration 24-week ramp + open-ended maintenance Off Period Community: 16-24 weeks on, 4-8 weeks off Best For Primary weight-loss strategy with full pathway coverage Approach Reta-first, cag add-on Duration Stabilize reta at 8-12 mg, then add cag for 12+ weeks Off Period Cag can be cycled on its own Best For Users already on retatrutide who want more satiety Approach Short-cycle test Duration 8-12 weeks at sub-maximal doses Off Period 4 weeks off Best For Initial tolerability check Taper retatrutide at the end of a cycle rather than stopping suddenly
Was telomerase measured directly
2022 July;208(1):34-42.Full text Engeler D, Baranowski AP, Berghmans B, et al
BPC-157 remains investigational with limited human clinical data
Tirzepatide + semaglutide or CagriSema better established